• VISTAAR is empowering Biopharma & Device teams with Product & Label Intel modules - Vistaar’s enhanced Product Analytics & Label Intelligence modules to enable researchers find deep insights of approved/marketed products for development and commercial needs VISTAAR, a provider of Regulatory and Clinical Intelligence solutions with AI driven technology for the life sciences industry, brings enhanced Product Analytics & Label Intelligence modules for Drug & Devices. Product Analytics provides holistic insights to regulatory and product teams to research available products in market, current global clinical development activity in those therapeutic areas and health agencies recent updates. All these presented in easily consumable dashboards and reports. Label Intelligence has more than 300K approved product labels (Drugs & Devices) from Canada, USA, UK, and EU. These are updated daily allowing user to conduct advanced searches (by company/product/indication and more options), perform a side by side comparisons of over 20 labels, and be notified on changes as they occur. Drug & Device product professionals may sign up and start experiencing the insights or visit VISTAAR website to learn more. About VISTAAR: VISTAAR is most up-to-date compared to any other Intel or data source because we use smart artificial intelligence methods all throughout. With a unique combination of technology and smart people, you will get your strategy and trusted insights much faster. Over many years, VISTAAR has built deep data sets to help you on your Regulatory and Clinical projects. All this done at the best price point in the industry. For more information, please visit http://www.vistaar.ai (Added: Thu Nov 12 2020 Hits: 67 Rating: 0.00 Votes: 0) Rate It

• VISTAAR is empowering Biopharma & Device teams with Product & Label Intel modules - Vistaar’s enhanced Product Analytics & Label Intelligence modules to enable researchers find deep insights of approved/marketed products for development and commercial needs VISTAAR, a provider of Regulatory and Clinical Intelligence solutions with AI driven technology for the life sciences industry, brings enhanced Product Analytics & Label Intelligence modules for Drug & Devices. Product Analytics provides holistic insights to regulatory and product teams to research available products in market, current global clinical development activity in those therapeutic areas and health agencies recent updates. All these presented in easily consumable dashboards and reports. Label Intelligence has more than 300K approved product labels (Drugs & Devices) from Canada, USA, UK, and EU. These are updated daily allowing user to conduct advanced searches (by company/product/indication and more options), perform a side by side comparisons of over 20 labels, and be notified on changes as they occur. Drug & Device product professionals may sign up and start experiencing the insights or visit VISTAAR website to learn more. About VISTAAR: VISTAAR is most up-to-date compared to any other Intel or data source because we use smart artificial intelligence methods all throughout. With a unique combination of technology and smart people, you will get your strategy and trusted insights much faster. Over many years, VISTAAR has built deep data sets to help you on your Regulatory and Clinical projects. All this done at the best price point in the industry. For more information, please visit http://www.vistaar.ai (Added: Thu Nov 12 2020 Hits: 83 Rating: 0.00 Votes: 0) Rate It

• 5th International Conference On Biopolymers & Polymer Chemistry - Welcome!! Scientific Federation welcomes you to attend and share your research at our upcoming “5th International Conference on Biopolymers & Polymer Chemistry” during September 23-25, 2021 in Venice, Italy We believe that during the three days of the conference, new knowledge and ideas will be presented, exchanged, and actively discussed between participants from diverse backgrounds and different countries. It gives us great pleasure to welcome all participants to enjoy rich, varied, and attractive scientific deliberations by expert and highly experienced speakers. Additionally, our future vision is to create even greater value for all corners of the globe. We have an exciting program at this conference that will allow members to reflect upon and celebrate our networks, and jointly explore current and future research directions. It will be one for us to share our thoughts and exchange ideas on how to chart our way forward to reach new heights. Conference Sessions: Nano Polymers and Modern Materials Bio Catalysis in Polymer Chemistry Polyhydroxy Alkanoates Polymer Rheology Characterization of Polymers Biocomposites Polymer Nanocomposite Biomaterials and Biopolymers Advances in Polymer Synthesis Conjugated Micro Porous Polymer Optoelectronic Polymers Supramolecular Polymers Polymer Technology Polymer Engineering Abstract Submission Link: https://www.scientificfederation.com/biopolymers-chemistry/abstract-submission.php (Added: Fri Nov 06 2020 Hits: 61 Rating: 0.00 Votes: 0) Rate It

• 5th Annual Meet on Obesity and Diet January 22-23, 2021 - 5th Annual Meet on Obesity and Diet going to be held in January 22-23 ,2021 Vienna, Austria. We invite you to join us at the Obesity and Nutrition Diet management meet 2021, where you will be sure to have knowledge with scholars from around the world for a good health. World-renowned speakers, the most recent methods, progresses, and the newest updates in Obesity Annual-2021 are hallmarks of this conference. (Added: Tue Nov 03 2020 Hits: 64 Rating: 0.00 Votes: 0) Rate It

• 2nd International Pharmaceutical and Novel Drug delivery Conference - 2nd International Pharmaceutical and Novel Drug delivery Conference Theme: Emerging trends in development of vaccines for Covid 19 Conference Brochure | Submit Abstract | Scientific Sessions Herald Meetings takes pleasure in inviting the scientific community across the globe to attend the 2nd International Pharmaceutical and Novel Drug delivery Conference during March 05-06, 2021 Which is an Online Webinar around the theme " Emerging trends in development of vaccines for Covid 19". About Conference Pharmaceutical 2021 fill in as a platform for the communication between specialists in the territories of pharmaceutics, drug delivery, nanomedicine, biotechnology and nanotechnology around the globe and points in sharing some one of a kind research and translational investigations on different advances in the related fields.The conference opens the doors for many researchers in academia, clinicians, and industry representatives working in these exciting areas.It is predicted to bring collectively each professional scientist in advanced stages of their profession and young researches from many related discipline Members Members Associated with Pharmaceutical: Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of: Eminent Scientists, Research Professors, Rectors Students and research scholars Members of different medical associations Governmental and public bodies Advocacy groups, Institutional Board members Societies Pharmaceutical 2021 is comprised of 18 tracks and 108 sessions designed to offer comprehensive sessions that address current issue. For more scientific sessions and abstract submission, please visit: https://pharmaceutical.heraldmeetings.com/submit-abstract Important links for the Conference: Abstractsubmission: https://pharmaceutical.heraldmeetings.com/submit-abstract BrochureDownload: https://pharmaceutical.heraldmeetings.com/brochure-download Registrationlink: https://pharmaceutical.heraldmeetings.com/registration Scientificsessions: https://pharmaceutical.heraldmeetings.com/call-for-abstract (Added: Sat Oct 17 2020 Hits: 57 Rating: 0.00 Votes: 0) Rate It

• 3 phase ac voltage regulator - The three-phase voltage regulator controls the input voltage and it can also be used as an output generator. It helps in increasing the voltage of the power supply. This type of power supply is used to regulate the voltage by controlling the electric power that is supplied by the power source. It can also be referred to as a three-phase motor. This type of motor is divided into three parts that include winding, control unit, and rotor. The winding of the three-phase motor is arranged in a way that it generates a torque or a force when it is turning. In this case, the power is supplied from the electrical energy and turned into electrical current. The same mechanism is applied to the rotor. In the design of the three-phase voltage regulator, the first component is called the control circuit. This is the component that monitors the voltage and controls the changes in the voltage. The second component is the protection circuit. This is used to reduce voltage fluctuations. It is used to increase the voltage to maintain the same level of power. This device regulates the power being supplied. The protection feature is to protect the device against current, under-voltage, short circuits, and low voltage. About Automatic Voltage Stabilizer For Sale These devices are most commonly found in online stores and used to charge and discharge electricity within their own self. This means that they are portable and are easily movable from place to place. There are also many of these types of devices that are used by businesses to use on their electrical wiring or to charge batteries to be used by electrical devices in order to charge them during the night. The fact that these devices are portable makes them even more attractive to many of the people who are looking to purchase one for their home. The price is also much lower than purchasing a static automatic voltage regulator for sale. The static type of regulator will not be moved around as much as the portable types, making them ideal for use in smaller areas. They are also a passive type of device, which means that they do not have any active or reactive components. They are very good at maintaining a steady level of electricity for you and your family to use. There are several different types of regulators that you can find that is capable of maintaining the flow of electricity. The active automatic voltage stabilizer for sale can charge batteries and devices at the same time and is able to do so in a very efficient manner. The fact that they can handle multiple tasks at once is a great asset to any home or a business owner. The fact that they are larger than the passive types is also another major plus. It is also possible to find a modern regulator that can regulate electricity for a home or business by using either a power cord or cordless technology. This means that the automatic voltage stabilizer for sale will not interfere with the functionality of electronic devices within a home or business. The flexibility of the device allows it to be used by more types of electronic devices within your home or business environment. The following items should be paid attention to when using a three-phase voltage stabilizer, which can increase the service life of the voltage stabilizer: If the fuse is burnt out, please approve the equipment to be worn as soon as possible, take repair measures in time, and restore power; If you use a fixed-rated fuse, please use the specified line and do not match it randomly, so as not to cause greater damage; Working under the specified conditions, do not use too high a load to avoid accidents; Prepare to choose the input voltage switch to ensure that it is consistent with the power supply voltage; It should be noted that the output voltage of the instrument and the regulator should be unified; Please use a long enough wire to avoid accidents. Repair in time; When inputting and outputting, be careful to link, and don't damage the equipment, which will cause rouble to the installation; The installation location of the three-phase voltage stabilizer must be in a dry and ventilated place. (Added: Fri Sep 25 2020 Hits: 84 Rating: 0.00 Votes: 0) Rate It

• syed nawaz cisco news press - syed nawaz cisco news press syed nawaz cisco news press Bay Area tech executives Syed Nawaz and CEO Jayavel Murugan who is the owner of Silicon Valley staffing firm, are Dynasoft's Chief Executive Officer (Added: Mon Sep 21 2020 Hits: 63 Rating: 0.00 Votes: 0) Rate It

• No.1 Vastu Experts in India | Vastu Shastra Expert Near You (2020) - No.1 Vastu Experts in India and get 100% geninue advice for your Home, Office, Flats & Business. Call Us Today +91-9582708882. Over 2M Happy Customers VastuShastrais necessary for living in positivity & harmony. Well, the directions of the Earth plays vitally in Vastuexpert in India. It is an ancient Indian architecture which is based on various directions & sub directions. It provides a well-planned architect for the construction of a home, building, industries or more if we build any structure or homes according to the ancient architect that attracts various positives energies for joyous living and call now Vastu experts in India. Call Now: +91-9582708882 Website: vastuexpertinindia.com (Added: Sat Sep 05 2020 Hits: 212 Rating: 0.00 Votes: 0) Rate It

• No.1 Vastu Experts in India | Vastu Shastra Expert Near You (2020) - No.1 Vastu Experts in India and get 100% geninue advice for your Home, Office, Flats & Business. Call Us Today +91-9582708882. Over 2M Happy Customers VastuShastrais necessary for living in positivity & harmony. Well, the directions of the Earth plays vitally in Vastuexpert in India. It is an ancient Indian architecture which is based on various directions & sub directions. It provides a well-planned architect for the construction of a home, building, industries or more if we build any structure or homes according to the ancient architect that attracts various positives energies for joyous living and call now Vastu experts in India. Call Now: +91-9582708882 Website: vastuexpertinindia.com (Added: Sat Sep 05 2020 Hits: 220 Rating: 0.00 Votes: 0) Rate It

• Soviet victory over Japan made decisive contribution to end of World War II - For the first time in the modern history, Russia will celebrate the end of World War II on September 3 – it will be the 75th anniversary of the USSR’s victory over Japan. The corresponding law that establishes a new date to commemorate Russian military glory was signed by Russian President Vladimir Putin on 24 April 2020. Previously, this change was adopted by the State Duma and approved by the Federation Council. Japan’s act of unconditional surrender was signed on 2 September 1945. It recorded the implementation of the Yalta Conference agreements regarding the transfer of South Sakhalin and the Kuril Islands under the sovereignty of the Soviet Union. On the same day, by the decree of the Presidium of the Supreme Soviet of the USSR, September 3 was declared a holiday of victory over Japan. However, the day of the national celebration – that is how it was indicated in this document – after only two years, in 1947, became a working day and was gradually forgotten as a holiday. The conclusion report of the Russian government for the bill on amendments to the Federal Law on Days of Military Glory and Commemorative Dates in Russia emphasized that the victory of the Soviet Union over Japan in 1945 made a decisive contribution to the end of World War II. According to the explanatory note to this bill, one of the initiators of which was Head of the State Duma Defense Committee, Hero of Russia, Colonel-General Vladimir Shamanov, over 300 thousand Soviet citizens were awarded orders and medals for exploits and military distinctions during the war with Japan; more than 1.8 million people were awarded the medal “For the victory over Japan,” on the reverse side of which there is an inscription “September 3, 1945”; and about 100 people were awarded the title of Hero of the Soviet Union. “The inscription ‘September 3 – Day of the end of World War II (1945)’ symbolizes the transition from a state of war to peace, the search for ways of reconciliation and cooperation. The day of the end of World War II is also celebrated in the allied states of the Soviet Union in the anti-Hitler coalition. For example, the Day of Victory of the Chinese People in the War of Resistance to Japan is widely celebrated on September 3 annually,” the document says. It also notes that in 2015, 12 foreign leaders, including Russian President Vladimir Putin and UN Secretary General Ban Ki-moon, took part in the festive anniversary events on this occasion. According to many historians, the defeat of Japan by Soviet troops was the logical culmination of Tokyo’s long-term aggressive policy in the Far East. Despite the pact of neutrality concluded in 1941 – two years after the border conflict on the Khalkhin-Gol River – Tokyo, in fact, kept the Kwantung grouping of troops numbering up to 1.5 million people near the territory of the USSR until the very end of World War II. This forced Moscow to maintain large covering forces in the Far East even at the most difficult stages of the war with Nazi Germany. After the signing of the pact, the Japanese have repeatedly violated the border of the Soviet state and carried out other provocative actions. Until the end of 1943, Tokyo was developing a plan of aggression against the Soviet Union. Although some Western and Japanese researchers share a widespread point of view about an allegedly “treacherous attack” on the Land of the Rising Sun, the USSR declared war on Japan in full accordance with the agreements reached at the Yalta and Potsdam conferences, and four months before had denounced the pact on neutrality in accordance with international law. Thus, Moscow demonstrated its readiness to fulfill its allied duty, in contrast to Great Britain and the United States, which evaded opening a second front for several years. The USSR war against Japan was of a liberating nature. It put an end to years of Japanese oppression of peoples in the region. At the same time, despite the readiness of the USSR allies to compensate for its the entry into the war by the annexation of new vast territories, Moscow refused any annexations, declaring only its desire to retrieve the Kuril Islands ceded to Japan in 1875 and South Sakhalin, which it had torn away in 1905. According to various estimates, by the summer of 1945, Japan had sufficient resources to continue the hostilities for several more years, since the United States did not manage to completely destroy its military and economic potential. According to the calculations of the American command, the war could drag on until 1947 and lead to a huge number of victims. Meanwhile, Tokyo, after inflicting unacceptable losses on US troops and creating a situation of strategic impasse, hoped to achieve an honorable peace through active defense of the metropolis and hoped to turn to Moscow for mediating assistance in negotiations with Washington in exchange for territorial concessions. In turn, the Western allies realized that they could not quickly end the war with Japan without the help of the USSR. The swift defeat of the most powerful and combat-ready formations of the Japanese ground forces by the Red Army in Manchuria and the loss of its industrial base located in Northeast China determined Tokyo’s decision to surrender. The command of the imperial armed forces intended to hold back the offensive in the Manchu direction for up to a year, but Soviet troops completely destroyed the Kwantung Army in 11 days. The military-political leadership of Japan decided to lay down arms on August 14, the day of the end of the main phase of the operation in Manchuria, which is known in the West as Operation August Storm. According to experts, this successful Soviet operation not only became the final chord in the end of World War II, but also significantly influenced the international situation in the Pacific region. At the same time, Western historiographers have long noted the alleged dominant role of the nuclear bombings of Hiroshima and Nagasaki, ignoring the decisive contribution of the Soviet Union to the victory. But the Japanese documents which recently appeared in the open access emphasize that Moscow, having declared war on Tokyo, thereby hastened the defeat of the Land of the Rising Sun. Thus, in the Rescript to Soldiers and Sailors of 17 August 1945, the commander-in-chief of the Japanese army and navy, Emperor Hirohito, called the USSR’s entry into the war the main reason for the surrender. “Now that the Soviet Union has also entered the war against us, continuing resistance ... means endangering the very foundation of our empire’s existence,” the document says. American atomic bombs and the destruction of cities are not mentioned in it. According to a number of analysts, the traditional position of the West on the decisive role of the bombing of Hiroshima and Nagasaki is understandable and convenient. For example, Ward Wilson, the author of The Five Myths About Nuclear Weapons, points out that this version satisfies the emotional needs of both the United States and Japan. “If the Bomb won the war, then the perception of US military power would be enhanced, US diplomatic influence in Asia and around the world would increase, and US security would be strengthened. The 2 billion dollars spent to build it would not have been wasted. If, on the other hand, the Soviet entry into the war was what caused Japan to surrender, then the Soviets could claim that they were able to do in four days what the United States was unable to do in four years, and the perception of Soviet military power and Soviet diplomatic influence would be enhanced. And once the Cold War was underway, asserting that the Soviet entry had been the decisive factor would have been tantamount to giving aid and comfort to the enemy,” says his article “The Bomb Didn’t Beat Japan … Stalin Did” published in Foreign Policy. Moreover, many experts not only do not consider the nuclear bombings of Japan to be a turning point in the war, but also speak of their absolute inexpediency. “There was no military necessity for this barbaric bombing. Today even some Western scholars admit this. In fact, Truman wanted, firstly, to intimidate the USSR with the destructive force of a new weapon, and secondly, to justify the enormous costs of developing it. But it was clear to everyone that the entry of the USSR into the war with Japan would put an end to it,” RT quotes Valery Kistanov, Head of the Center for Japanese Studies at the Institute of the Far East of the Russian Academy of Sciences. Peter Kuznick, Professor of History, Director at Nuclear Studies Institute, American University, also called it a myth that the Hiroshima and Nagasaki nuclear attacks ended the war. “It was actually the invasion by the Red Army on August 8 [at 18.00 Moscow time, at midnight Zabaikalsky time] that forced the Japanese surrender. This came as no surprise. US intelligence had been predicting this as early as April. On April 11, 1945, the Joint Intelligence Committee of the Joint Chiefs of Staff reported, ‘If at any time the USSR should enter the war, all Japanese will realize that absolute defeat is inevitable’,” he said. “The May 16 statement issued by Japan’s Supreme War Council said clearly, ‘Soviet entry into the war will deal a death blow to the Empire.’ After lunching with Stalin on July 17 at Potsdam, Truman wrote in his diary that Stalin will ‘be in the Jap War on August 15. Fini Japs when that comes about.’ He wrote home to his wife Bess the next day that Russia was coming in and ‘We'll end the war a year sooner now, and think of the kids who won't be killed!’ And that is exactly what happened,” Peter Kuznick reminded. According to him, the Soviet invasion undermined Japan’s Ketsu-go strategy and precipitated surrender. Japan’s leaders, cruel as they were, accepted the fact that the U.S. could wipe out their cities. Destruction reached as high as 99.5 per cent in the city of Toyama. To them, Hiroshima and Nagasaki were just two more cities. What changed the strategic situation was the Soviet entry. The top officials gathered at the residence of Foreign Minister Togo on the morning of August 9, prior to the Nagasaki bomb, and agreed that what they most dreaded had occurred. […] When Prime Minister Suzuki was asked on August 13 why Japan could not delay surrender he responded, ‘I can’t do that. If we miss today, the Soviet Union will take not only Manchuria, Korea, Karafuto, but also Hokkaido. This would destroy the foundation of Japan. We must end the war when we can deal with the US’,” the historian gave a quote. Much like with the even more obvious case of the Soviet Union deserving but no longer receiving credit for the victory over the Nazis in Europe, many Western historians downplay or belittle the Soviet role in defeating Japan as they have several reasons for this, he said. “First, the Soviets were only in the war very briefly whereas the Allies had been slogging it out for several years. Second, they want to deny the Soviet Union any credit for defeating fascism and Japanese militarism in order to maintain the fiction that the mighty United States singlehandedly defeated the bad guys in WWII and therefore deserved to become the leader of the ‘free world.’ This is tied up with both the idea of American exceptionalism and of American righteousness in the Cold War,” Peter Kuznick said. Moreover, according to him, it also fit into the anti-Soviet narrative that emerged in the postwar period. “It took a great effort on the part of Truman and his advisors to transform the Soviets from gallant wartime allies to dangerous, freedom-hating enemies who were out to conquer the world. Everything good about them had to be denied. Had Franklin Delano Roosevelt lived or had Henry Wallace remained as vice president and replaced Roosevelt upon his death on April 12, I’m convinced there would have been no Cold War and no nuclear arms race. That entire sordid chapter in human history might have been averted,” he suggested. In his opinion, the countries are still living with malign consequences of that period. “If the Soviet role were acknowledged, it would obviate the need for the atomic bombs, thereby further jeopardizing America's claim to moral leadership in the world. The irony is that those historians who attribute the surrender to the atomic bombs and not Soviet entry are also effectively downplaying and demeaning the extraordinary sacrifice made by US troops in the Pacific War, which set the preconditions for the Soviet invasion and the Japanese surrender,” the expert said. “There are two other important considerations. First, because the Japanese were trying to get the Soviets to intercede on their behalf to help them secure better surrender terms, Soviet leaders knew better than anyone how desperate the Japanese were to surrender and how unnecessary the bombs were. As a result, and as prescient U.S. scientists had warned would be the case, they interpreted the bombs as a ruthless US warning of what would happen to the USSR if it interfered with postwar US plans in Europe or Asia,” Peter Kuznick added. In turn, Jacques Sapir, Director of studies at the School for Advanced Studies in the Social Sciences (EHESS) in Paris, Head of the Center for Research of Industrialization (CEMI-EHESS), Foreign Member of the Russian Academy of Sciences, noted that one of the reasons for the relative obscurity in which the Soviet offensive was plunged, despite its success, can be understood from the extraordinary novelty represented by the two atomic weapons launched on Hiroshima and Nagasaki. “With these two bombings began the age of nuclear deterrence, an age that still lasts today. However, it must be remembered that until their use, atomic weapons remain a major unknown for the American military. No one knew what their exact power would be. That is why the American leadership called on the USSR to declare war on Japan. In July 1945, everyone thinks that Japan, despite the destruction of its military and civilian fleet, will resist until 1946. The United States has planned a landing in Japan, and so that the latter does not transform not in a bloodbath, they need the Japanese not to be able to bring all or part of the Kwantung army back to Japan. This is the reason for their insistence on Stalin to attack Manchuria,” the expert said. According to him, the use of nuclear weapons then caused a psychological shift in the Japanese leadership, giving the upper hand to supporters of surrender against supporters of all-out war. “Japanese leaders who favour surrender will use the novelty and ‘monstrous’ nature of nuclear weapons to impose their point of view. In fact, the United States no longer has nuclear weapons after the bombing of Nagasaki. But, that the Japanese leaders do not know,” Jacques Sapir reminded. Meanwhile, from his point of view, the Soviet contribution to the defeat of Japan in 1945 must be put into perspective with the battles that took place between Japanese and Soviet forces in 1939 at Khalkin-Ghôl: the heavy defeat suffered by the Japanese forces had led them to adopt a defensive posture against the USSR. “At the Yalta conference, in February 1945, Stalin accepted the entry into the war of the USSR against Japan within three months after the defeat of Germany, the USSR receiving in exchange the south of the island of Sakhalin and the Kuril Islands. The Soviet offensive, carefully prepared and remarkably commanded by Marshal Vassilievsky, Marshal Malinovsky and Marshal Meretskov, launched on August 8, resulted in a total defeat of the Japanese Kwantung Army. This army consisted of 990,000 men and 1,155 tanks to which were added more than 210,000 auxiliaries. Facing it, the Soviet army had deployed 1.5 million men and 5,600 tanks and assault guns, organized into three ‘Fronts’, that of Trans-Baikalia, and the 1st and 2nd Fronts of the Far East,” the foreign member of the Russian Academy of Sciences said. “This operation was carried out on three axes, from West to East through the Trans-Baikal front through the Great-Khingan range, from North to South and East to West from Vladivostok. These three axes of attack completely surprised the Japanese General Staff. The offensive across the Great-Khingan Mountains caused the complete collapse of the Japanese defence. The 2nd Far Eastern Front also advanced very quickly towards Mutanchiang, which was taken after heavy fighting on August 14 and 15. Japanese forces were surrounded on August 16 and surrendered on August 20, although isolated elements fought until August 26. The Manchurian operation is regarded as the ‘masterpiece’ of Soviet military art, and with good reason. The Soviet forces demonstrated not only material but conceptual superiority over the Japanese forces which were never able to defend themselves in an organized manner and could only endure the Soviet offensive,” Jacques Sapir said. Meanwhile, Lewis Siegelbaum, Professor Emeritus of History, Michigan State University, expressed the opinion which is popular in the West: the contribution of the USSR to the defeat of the Japanese “was important, but not decisive.” “Sadly, the dropping of the two atomic bombs on Hiroshima and Nagasaki proved so overwhelmingly horrifying, that it sapped the will of the Japanese authorities to continue hostilities. The Soviet entry into the war – on the very day that Stalin had indicated at Yalta it would occur – facilitated the Japanese capitulation. Given the weakened state of the Japanese armed forces, the prospect of thwarting the Soviet army’s invasion seemed even less realistic than it would have otherwise,” the expert said. He also stressed that in more general terms, one should not treat American and Soviet efforts as mutually exclusive or a zero-sum situation. “The Japanese might have assumed that they could play one against the other, but even though the Truman administration did not inform its ally that it had decided to proceed with the "nuclear option" - or even that it possessed the means to do so - and, as many historians have argued, decided to drop the bombs in part to limit Soviet gains at the expense of the Japanese, Stalin continued to operate in accordance with allied agreements,” Lewis Siegelbaum said. Meanwhile, Professor Martin J. Sherwin, Department of History & Art History, George Mason University, stressed that it was the Soviet Union’s declaration of war on Japan on August 8, 1945, that forced the Japanese to surrender. “The Japanese military could not fight a two-front war and its government was extremely anti-communist. The thought of the Soviet Union participating in the occupation was the Japanese government’s worst nightmare, and all correctly assumed that Stalin would seize the territories Russia had lost in the 1905 Russo-Japanese war plus Hokkaido. Surrender to the US suddenly became the best option,” the historian explained. Analyzing the reasons why the West is still making enormous efforts to distort and belittle the role of the Soviet Union in ending World War II, Martin Sherwin pointed out that this position was and still remains beneficial for the American leadership. “The American government promoted the idea that the atomic bomb ended the war and prevented an invasion. That made sense in 1945 and the growing rift between the US and USSR prevented any public consideration of the idea that it was the Soviet Union’s entry into the war rather than the atomic bomb that brought Japan to surrender. The current state of US-Russian relations continues to influence that history,” the expert concluded. (Added: Mon Aug 31 2020 Hits: 63 Rating: 0.00 Votes: 0) Rate It

• International Conference on Science, Engineering & Technology (ICSET-2021) - The international Conference on Science, Engineering & Technology (ICSET-2021), which is scheduled to take place on the 28th and 29th of January, 2021 in the stunning city of Singapore will offer researchers, delegates and scholars an incredible chance to interact with each other and share their experience and knowledge of technology application. ICSET-2021 in Singapore will serve as an excellent international conference for intelligence sharing. The goal of the conference is to provide a stage for researchers and practitioners from academia and business to deal with state-of-the-art advancement in their respective fields. An inventor is a communications professional, involved with applying objective knowledge, science and resourcefulness to generate resolutions for technical, cultural and enterprise problems. Therefore, the ideal designer is a composite and must operate at the interface between art and culture. (Added: Thu Aug 27 2020 Hits: 268 Rating: 0.00 Votes: 0) Rate It

• Bruker and Purity-IQ sign partnership agreement to transform the cannabis regulatory landscape - Bruker and Purity-IQ have joined forces to create a powerful new testing system for medical cannabis in Canada. The Purity-IQ Cannabis Fingerprint™ combines Bruker’s expertise in nuclear magnetic resonance (NMR) based screening technology with Purity-IQ’s genomics capabilities to offer traceability and identity testing throughout the cannabis supply chain. There are currently no standardized regulations between states or countries for quality control in cannabis, making it difficult for consumers to make informed decisions about the product they are purchasing. Bringing two powerful technologies together gives the supply chain the opportunity to move the cannabis industry to a consistent and compliant platform. Cannabis producers and manufacturers need to ensure product quality and consistency of strain and dosage, especially as regulatory standards continue to shift, and retailers such as pharmacies and dispensaries must protect their brand and provide consumers with a product they can trust. Identifying the genomic profile and chemical compounds in a cannabis cultivar is the key to providing consistent quality and dosing assurance. The Purity-IQ Global Cannabis Registry™ is the only database derived from the genomic and metabolomic identification of cannabis and hemp products, and will serve to satisfy the industry need for tracking and tracing within the supply chain. Genomics is used to determine cannabis identity and heredity and NMR determines the purity and consistency of the product at a molecular level, providing traceability, authenticity and identity throughout the supply chain from plant to finished product. This is achieved through creating a unique chemical “fingerprint,” using the Purity-IQ Cannabis Fingerprint™ to create new Cannabis Authenticity and Purity Standard (CAPS). Dr. Henry Stronks, President of Bruker Canada, comments: “A genetic fingerprint alone is not enough to produce a full picture. To generate a complete fingerprint, cannabis strains must also be profiled using NMR technology. Pattern recognition allows us to identify peaks that correspond to the pharmacological properties of the cannabis, its geographical location, strain, hybrid and quality. We believe this is the first step for the cannabis industry in providing safe, uniform and effective products founded in combined genomics and metabolomics testing.” NMR offers many advantages compared to other technologies available on the market. As an untargeted analysis method, it gives a comprehensive view on the metabolome. NMR is inherently quantitative making it easy to determine the relative concentrations of substances in a mixture accurately and rapidly. Terry Dennis, Chief Marketing Officer at Purity-IQ comments on the benefits of the collaboration with Bruker: “CAPS recognition will identify and differentiate products, build intellectual property, ensure authenticity, drive confidence in product quality claims, allow access to new markets, and protect brand reputation. There is a whole host of other sectors that would benefit from the combination of genetic and metabolomic fingerprinting, particularly in the food and beverage industry in the fight against food fraud. This will support the whole value chain and, one day, consumers will have full transparency, trust and confidence in all products they buy.” Bruker’s unique NMR based screening technology is well established and tailored specifically for the analysis of food. The FoodScreener™ provides the NMR fingerprint specific to an individual sample. The profile can then be compared with a large database of spectra for known authentic samples. This innovative instrument provides a valuable tool for quality control monitoring and testing for purity and authenticity issues. The key element of the newly formed partnership of Purity-IQ and Bruker is to apply this technology to the cannabis industry. Bruker’s 400 MHz NMR spectrometer and its Fourier 80 benchtop NMR system are installed at the University of Guelph, Canada, where Bruker’s and Purity-IQ’s scientists collaborate in research and development with the Natural Health Products (NHP) Research Alliance, a collaborative body based at the University of Guelph, creating novel DNA-based ingredient identity tools founded on a global standard biological reference materials DNA library for natural health products. (Added: Mon Aug 24 2020 Hits: 73 Rating: 0.00 Votes: 0) Rate It

• Growth Demand on Betulinic Acid Market Share are Rising by 2020-2025 - Betulinic Acid Market 2020 Global Industry research report studies latest Betulinic Acid industry aspects market size, share, trends, growth, business overview and Betulinic Acid industry scenario during the forecast period (2020-2025). Overview of Global Betulinic Acid Market: Betulinic acid is a naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial, and anti-inflammatory properties, as well as a more recently discovered potential as an anticancer agent, by inhibition of topoisomerase. It is found in the bark of several species of plants, principally the white birch (Betula pubescens) from which it gets its name, but also the ber tree (Ziziphus mauritiana), selfheal (Prunella vulgaris), the tropical carnivorous plants Triphyophyllum peltatum and Ancistrocladus heyneanus, Diospyros leucomelas, a member of the persimmon family, Tetracera boiviniana, the jambul (Syzygium formosanum), flowering quince (Pseudocydonia sinensis, former Chaenomeles sinensis KOEHNE), rosemary and Pulsatilla chinensis. The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Betulinic Acid market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects. Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273652 . Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Betulinic Acid costs and an increase in the number of selective inhibitor of human melanoma. Product Type Segmentation: The Betulinic Acid market have different product type such as Above 99%, Above 98% and Others. Betulinic Acid market product type gives apoptosis in human neuroblastoma in vitro and in vivo in model systems. Industry Segmentation: Increasing instances across various sectors such as Actinic Keratosis, Antiphlogistic Activity, Cancer, HIV and Other are raising the need of chemical institutes, thereby raising the demand for Betulinic Acid market. This help in the profitable growth of the Global Betulinic Acid market in upcoming year. Segmentation by Regions: The Betulinic Acid market in North America has created drug with assistance from the Rapid Access to Intervention Development program of the National Cancer Institute in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Betulinic Acid Market during the forecast year. Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Betulinic Acid Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273652/single . Top Leading Key Manufacturers are: Aphios, Manus Aktteva Biopharma, Shaanxi Yuanyu Biological, FOODCHEM, Hangzhou Dayangchem, Wilshire Technologies, Simagchem Corporation, Capot Chemical, X´ian Taicheng Chem, Hangzhou Meite Chemical. New product launches and continuous technological innovations are the key strategies adopted by the major players. Top Industry News: Aphios Granted US Patent for Combination HIV Latency Nanotherapeutic Towards an HIV Cure on 28 Jan, 2020 -- Aphios Corporation today announced that it was issued US Patent No. 10,493,030 for the treatment of HIV latency towards an HIV cure. Since the start of the HIV/AIDS pandemic in 1982, over 32 million people have died from AIDS and there were approximately 37.9 million people living with HIV in 2018. In the United States, an estimated 1.1 million people are currently living with HIV and approximately 40,000 new infections occur each year. AIDS-related mortality has fortunately declined by 33% since 2010. Even with these encouraging statistics, the total number of persons infected increases about 1 million per year in the absence of a cure since the annual average rate of new infections is approx. 1.7 million and the average number of deaths globally is approx. 770,000. A cure for HIV is urgently needed to bend the curve towards ending this pandemic affecting more than 38 million people worldwide. HIV infects several cell types during the course of infection and progression to AIDS. Antiretroviral (ART) is very effective in controlling replication of the virus in most cells. HIV, however, establishes latent long-term infection in a small pool of memory CD4+ T (immune) and other cells, which contain integrated but transcriptionally silent HIV provirus. These cellular virus reservoirs are a potential source of rapid HIV virus reactivation and progression to AIDS if ART is stopped for any reason. There are no commercially available drugs for treating HIV latency and/or curing HIV. The Aphios ’030 patent is for a combination of two Latency Reversal Agents (LRAs) — a Protein Kinase C (PKC) modulator of the anti-tumor class, ‘Bryoids’ and a Histone Deacetylase (HDAC) inhibitor co-encapsulated in long-circulating pegylated immuno-nanosomes to purge latent HIV from cellular reservoirs. Bryoids, such as Bryostatin-1, activate cellular transcription factors such as NF-κB which transcribes latent HIV into active HIV virus. The HDAC inhibitor removes acetyl groups affecting gene expression and increases accessibility of NF-κB improving transcription efficacy. By combining a PKC modulator and HDAC inhibitor in the same nanoparticle, both drugs reach their intended target simultaneously. These nanoparticles can be coated with targeting ligands to reach their target and with anti-PDL-1 nanobodies to keep CD4+ T-cells activated for clearance of re-activated HIV-1 virus. These immuno-nanosomes will reduce systemic toxicities while pegylation increases nanoparticle biological residence time to increase therapeutic efficacy and overall therapeutic index. Dr. Trevor P, Castor, CEO, Aphios and inventor of the issued patent states that “HIV/AIDS is a pandemic we are still battling on par with pandemics of the past such as the 14th century Bubonic Plague and the 20th century Spanish Flu. The end can sometimes seem to be a long way away, but a cure for HIV is realizable within our lifetime. APH-0812 is designed to activate latent HIV reservoirs for clearance by ARVs and/or the patient’s immune system, and eliminate the long-term economic burden of ARV drug costs, associated drug-induced side effects and social stigma.” Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273652 . Major Points in Table of Contents: 1 Betulinic Acid Product Definition 2 Global Betulinic Acid Market Manufacturer Share and Market Overview 2.1 Global Manufacturer Betulinic Acid Shipments 2.2 Global Manufacturer Betulinic Acid Business Revenue 2.3 Global Betulinic Acid Market Overview 3 Manufacturer Betulinic Acid Business Introduction 3.1 Aphios Betulinic Acid Business Introduction 3.1.1 Aphios Betulinic Acid Shipments, Price, Revenue and Gross profit 2020-2025 3.1.2 Aphios Betulinic Acid Business Distribution by Region 3.1.3 Aphios Interview Record 3.1.4 Aphios Betulinic Acid Business Profile 3.1.5 Aphios Betulinic Acid Product Specification 3.2 Manus Aktteva Biopharma Betulinic Acid Business Introduction 3.2.1 Manus Aktteva Biopharma Betulinic Acid Shipments, Price, Revenue and Gross profit 2020-2025 3.2.2 Manus Aktteva Biopharma Betulinic Acid Business Distribution by Region 3.2.3 Interview Record 3.2.4 Manus Aktteva Biopharma Betulinic Acid Business Overview 3.2.5 Manus Aktteva Biopharma Betulinic Acid Product Specification 3.3 SHAANXI YUANYU BIOLOGICAL Betulinic Acid Business Introduction 3.3.1 SHAANXI YUANYU BIOLOGICAL Betulinic Acid Shipments, Price, Revenue and Gross profit 2020-2025 3.3.2 SHAANXI YUANYU BIOLOGICAL Betulinic Acid Business Distribution by Region 3.3.3 Interview Record 3.3.4 SHAANXI YUANYU BIOLOGICAL Betulinic Acid Business Overview 3.3.5 SHAANXI YUANYU BIOLOGICAL Betulinic Acid Product Specification 3.4 FOODCHEM Betulinic Acid Business Introduction 3.5 HANGZHOU DAYANGCHEM Betulinic Acid Business Introduction 3.6 Wilshire Technologies Betulinic Acid Business Introduction ………………. Request free sample to get a complete Table of Content About us BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Media Contact Business Industry Reports Pune – India sales@businessindustryreports.com +19376349940 (Added: Wed Aug 12 2020 Hits: 62 Rating: 0.00 Votes: 0) Rate It

• Global Wireless Electrocardiography (ECG) Devices Market 2020-2026 - Global wireless electrocardiography market is expected to reach $2,276.1 million by 2026, representing a 2020-2026 CAGR of 6.05%. Highlighted with 81 tables and 68 figures, this 153-page report “Global Wireless Electrocardiography (ECG) Devices Market 2020-2026 by Product Type, Device Modality, End User, Distribution Channel, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global wireless electrocardiography market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify global wireless electrocardiography market in every aspect of the classification from perspectives of Product Type, Device Modality, End User, Distribution Channel, and Region. More Info: https://www.autumnmarketresearch.com/industry-reports/global-wireless-electrocardiography-ecg-devices-market-2020-2026-by-product-type-device-modality-end-user-distribution-channel-and-region-trend-forecast-and-growth-opportunity/ Email Id: info@autumnmarketresearch.com Phone no: 07022899215 (Added: Thu Aug 06 2020 Hits: 249 Rating: 0.00 Votes: 0) Rate It

• ARCpoint Labs of Monterey Bay Offers Five Different COVID-19 Tests - ARCpoint Labs of Monterey Bay is now offering two live virus tests and three antibody tests for COVID-19, but which one is the right one for you? Monterey, CA, July 22, 2020 — ARCpoint Labs of Monterey Bay is now offering two live virus tests and three antibody tests for COVID-19, but which one is the right one for you? “The different COVID-19 tests available can be divided into two main types, which answer different questions,” said Spenser Smith, lab director at ARCpoint Labs. “Are you more concerned with whether you are potentially infected right now, at the time of testing? Or are you more interested in whether you may have been infected in the past, potentially several weeks or months ago, and have since recovered? If you are concerned about being infected now, maybe even contagious, then you want a live virus test. These tests detect the presence of SARS-CoV-2 (the virus that causes COVID-19) by looking for the virus’ molecular signature directly. Typically, these tests use a nasal/oral swab or saliva sample. If you test positive with a live virus test, you are carrying virus right now and should be assumed to be contagious, even if you are experiencing mild or no symptoms. If you test negative that means no virus was detected, though in some cases a physician’s judgment or further evaluation is needed to understand if your results may be a false negative. There are two live virus testing methods which differ primarily in accuracy and how long results take to process. The first is an Antigen Rapid Test, which requires a nasal or other swab, with a 24-hour turnaround time, a 94% true positive rate, 100% true negative rate, no doctor’s order is required, $130. The second is a PCR NAAT Lab-based test, which also requires a nasal or other swab, with a 2-to-5-day turnaround time, a 99% true positive rate, 100% true negative rate, a doctor’s order is required, $130. Some people may be more interested in whether they have had COVID-19 at some point in the past. Perhaps they had symptoms weeks ago, but were never able to obtain a live virus test, perhaps they are curious if they may have been an asymptomatic case. Antibody testing is used to screen for past infection by COVID-19. If you test positive for COVID-19 antibodies, that means you have encountered COVID-19 in the past. In some cases, a positive for IgM or IgA may indicate current infection as well. Though COVID-19 antibodies seem to indicate resistance to future reinfection, individuals who test positive should still follow face covering, hand washing and social distancing guidelines to protect themselves and others. If you test negative for COVID-19 antibodies, you have not likely been exposed to COVID-19 at any time before and should be considered susceptible to infection. ARCpoint Labs offer three antibody tests to determine past infection. All three require drawing blood. One, a Qualitative Past Exposure Test, which has a three-to-seven-day turnaround, five-plus weeks recommended time since exposure, positive-negative results only, 100% true positive rate, 99.4% true negative rate, $49. The second is an IgG only Semiquantitative Test, one-to-four-day turnaround, five-plus weeks recommended time since exposure, semiquantitative value, 100% true positive rate, 99.4% true negative rate, $120. The third is a Combination Antibody Test (IgG+IgM+IgA), one-to-four-day turnaround, two-plus weeks recommended time since exposure, Semiquantitative value, 100% true positive rate, 99.8% true negative rate, $180. If you have questions about ARCpoint Labs COVID-19 testing, go to www.labtestmonterey.com or call (831) 324-0772. You always speak directly to a local testing expert at ARCpoint Labs. ABOUT ARCPOINT LABS ARCpoint Labs is a full-service national third-party provider and administrator of accurate, reliable, and confidential diagnostic testing for individuals, companies, and legal and healthcare professionals. ARCpoint Labs has been in the drug and alcohol testing business for over 18 years, and our staff has over 60 years of combined industry experience. ARCpoint Labs has over 100 locations across the country with an additional 18 locations slated to open within the next 12 months. For more information on ARCpoint Labs, visit www.arcpointlabs.com. ARCpoint Labs of Monterey Bay is an independently owned ARCpoint Labs business, part of a Greenville, South Carolina-based franchise. The Smith family of Monterey, brothers Spenser and Bryant and their parents Belle and Randy, established the company in 2018. ARCpoint Labs of Monterey Bay 24560 Silver Cloud Court, #103 Monterey, CA 93940 Phone: (831) 324-0772 Email: monterey@arcpointlabs.com Website: www.arcpointlabs.com COVID-19 Appointments: labtestmonterey.com Contact: Marci Bracco Cain Chatterbox PR Salinas, CA 93901 (831) 747-7455 http://www.arcpointlabs.com (Added: Wed Jul 22 2020 Hits: 68 Rating: 0.00 Votes: 0) Rate It

• HYDRO MANIA CORP LAUNCHES (HMC) Plant Tissue Collection Project - HYDRO MANIA CORP LAUNCHES (HMC) Plant Tissue Collection Project HYDRO MANIA CORP (HMC) will grow edibles, tropical and specialty plants. Their tissue culture laboratories will have the ability to produce millions of contaminant-free elite plants for all types of markets. The key benefits of tissue culture are consistent quality, juvenile vigor, superior branching, and true to type plants at a rapid pace. Hydro Mania Corp Chief Operating Officer, Anthony M. Jackson II says “there are 33 biotechnology companies engaged in Plant Tissue Culture work in the USA. And Hydro Mania Corp is proud to be a bit unusual amongst our competitors. In fact, there’s really not another company like us. “ HYDRO MANIA CORP manufactures and supplies soil and soil-less hydroponic grow products for both consumer and commercial plant growers. They plan to conduct research and micro propagation (including tissue culture media, plant growth regulators, agars, biochemical and much more). Hydro Mania Corp (HMC) CEO and President, Maurice A. Berkeley says “Our core purpose is to “Save and Improve Lives” through providing a safe, reliable and efficient supply of plant matter components, plant stem cells, culture tissues and related diagnostic services for both medical and pharmaceutical use.” HYDRO MANIA CORP (HMC) is operationally unique and has characteristics that cannot be found anywhere else apart from similar services in other countries. Mr. Berkeley adds “Our ambition is simple; we aim to be recognized as the best service of our type in the world, and evidence this through appropriate benchmarking. For more information: admin@everythingyouneedtogrowyourown.com corporate@theberkeleycapitalgroup.com WWW.EVERYTHINGYOUNEEDTOGROWYOUROWN.COM (Added: Tue Jul 21 2020 Hits: 66 Rating: 0.00 Votes: 0) Rate It

• HYDRO MANIA CORP LAUNCHES (HMC) Plant Tissue Collection Project - HYDRO MANIA CORP LAUNCHES (HMC) Plant Tissue Collection Project HYDRO MANIA CORP (HMC) will grow edibles, tropical and specialty plants. Their tissue culture laboratories will have the ability to produce millions of contaminant-free elite plants for all types of markets. The key benefits of tissue culture are consistent quality, juvenile vigor, superior branching, and true to type plants at a rapid pace. Hydro Mania Corp Chief Operating Officer, Anthony M. Jackson II says “there are 33 biotechnology companies engaged in Plant Tissue Culture work in the USA. And Hydro Mania Corp is proud to be a bit unusual amongst our competitors. In fact, there’s really not another company like us. “ HYDRO MANIA CORP manufactures and supplies soil and soil-less hydroponic grow products for both consumer and commercial plant growers. They plan to conduct research and micro propagation (including tissue culture media, plant growth regulators, agars, biochemical and much more). Hydro Mania Corp (HMC) CEO and President, Maurice A. Berkeley says “Our core purpose is to “Save and Improve Lives” through providing a safe, reliable and efficient supply of plant matter components, plant stem cells, culture tissues and related diagnostic services for both medical and pharmaceutical use.” HYDRO MANIA CORP (HMC) is operationally unique and has characteristics that cannot be found anywhere else apart from similar services in other countries. Mr. Berkeley adds “Our ambition is simple; we aim to be recognized as the best service of our type in the world, and evidence this through appropriate benchmarking. For more information: admin@everythingyouneedtogrowyourown.com corporate@theberkeleycapitalgroup.com WWW.EVERYTHINGYOUNEEDTOGROWYOUROWN.COM (Added: Tue Jul 21 2020 Hits: 66 Rating: 0.00 Votes: 0) Rate It

• Êóïèòü XBOX èãðû ðàçíîîáðàçíûå èãðû: UFC XBOX - Çäåñü âû ìîæåòå Êóïèòü èãðû íà XBOX ONE ïðèñòàâêó + https://vk.com/public195417980 (Added: Tue Jul 14 2020 Hits: 68 Rating: 0.00 Votes: 0) Rate It

• VulcanChem Provides Quality Compounds of Potential Cures for COVID-19 Research - VulcanChem (California, USA) and its collaborating facilities are providing research-grade compounds of potential drugs to help to accelerate the ongoing research to find a cure. California, USA., July 1st 2020 -- Over 10 million people worldwide have tested positive for the novel coronavirus and that number is quickly growing. The healthcare system is becoming increasingly strained and the world are in desperate need of a safe and effective treatment for COVID-19. Scientists around the world are racing against time to find a cure/drug. VulcanChem (California, USA) and its collaborating facilities are providing research-grade compounds of potential drugs to help to accelerate the ongoing research to find a cure. Please note that the following items are for research use only. Not for human or veterinary use. 1) Remdesivir Remdesivir is an antiviral that is given by intravenous (IV) infusion in the hospital. This is a brand-new drug that has not been approved by the FDA for use on the market yet, and is being tested in carefully controlled environments. It was previously shown to have some effect against SARS, MERS, and Ebola in cell and animal models. In a recent in vitro study (studies done in a petri dish or test tube rather than in animals or humans), remdesivir prevented human cells from being infected with SARS-CoV-2 (the virus that causes COVID-19). For more information: https://www.vulcanchem.com/product/inhibitors/VC1031201 2) Dexamethasone Dexamethasone is a common corticosteroid (steroid) medication that has been used for many years to treat various health conditions, such as autoimmune conditions and allergic reactions. RECOVERY, a randomized clinical trial in the UK, is studying many medications, including dexamethasone, to see if any are effective against COVID-19. For more information: https://www.vulcanchem.com/product/inhibitors/VC1051515 3) Hydroxychloroquine and chloroquine Hydroxychloroquine and chloroquine are two medications that have been used for many decades to treat malaria and autoimmune conditions like rheumatoid arthritis and lupus. A few small studies suggest that they may also be helpful for treating hospitalized patients with mild cases of COVID-19, while many other studies showed that hydroxychloroquine did not make a difference. More robust studies are needed to confirm whether these medications actually work. `For more information: https://www.vulcanchem.com/product/inhibitors/VC1031211 4) Azithromycin Azithromycin (informally known as a Z-pak) is an antibiotic commonly used to treat bacterial infections such as bronchitis and pneumonia. It has been shown to have some in vitro activity against viruses like influenza A and Zika, but did not work against the coronavirus that causes MERS. For more information: https://www.vulcanchem.com/product/inhibitors/VC1040653 5) Avigan (favipiravir) Favipiravir (also known as Avigan) is an antiviral medication approved in Japan and China for the flu. In vitro studies have shown that high doses of favipiravir were able to prevent human cells from being infected with SARS-CoV-2. For more information: https://www.vulcanchem.com/product/inhibitors/259793-96-9 6) Colcrys (colchicine) Colchicine is a medication used for gout. It works in many different ways, including activating anti-inflammatory processes and interfering with cells involved in inflammation. Researchers think that colchicine could work similarly to Actemra in COVID-19 patients in that it might be helpful if the immune system becomes too activated and a cytokine storm occurs. A large clinical trial is currently seeing if colchicine, when given soon after a COVID-19 diagnosis, can lower the chances of hospitalization and death. For more information: https://www.vulcanchem.com/product/inhibitors/VC1048349 7) Ivermectin Ivermectin is an oral medication used to treat infections caused by parasites. It is also available as a lotion or cream to treat lice and rosacea. A recent in vitro study found that ivermectin can stop SARS-CoV-2 from replicating. A lot more research is needed to see if the doses studied would be safe and effective against the virus in humans. For more information: https://www.vulcanchem.com/product/inhibitors/VC1062099 8) Tamiflu (oseltamivir) Tamiflu is an antiviral medication used for influenza (flu). Results from a hospital in Wuhan, China were not promising. Of 138 hospitalized patients, 124 got Tamiflu along with other medications. By the end of the study, 85 patients (62%) were still hospitalized and 6 had died. Nonetheless, several clinical trials are currently looking at Tamiflu in combination with other medications for coronavirus. For more information: https://www.vulcanchem.com/product/reference-standards/196618-13-0 There is no cure or vaccine for COVID-19 at this time. More studies are needed to confirm if any of the potential treatments listed above will work for COVID-19. Research on COVID-19 is rapidly evolving. For now, the treatment for patients with mild symptoms is to self-isolate at home. Patients who are hospitalized receive supportive care (such as oxygen), enroll in clinical trials, and are given medications off-label based on hospital guidelines and their doctors’ clinical judgement. About VulcanChem: Headquartered in California, USA, VulcanChem is a global leading manufacturer and supplier of specialty chemicals of high-quality including building blocks, novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. We now have representatives or branch offices on the East Coast of the US, and in Europe and Asia. Our clients include academic, industrial and government research and development laboratories as well as commercial scale businesses in the pharmaceutical and chemical industries. Contact: Valerie Walters VulcanChem 680 East Colorado Boulevard Pasadena CA 91101 USA +1 626-817-6683 pr@vulcanchem.com https://www.vulcanchem.com (Added: Sat Jul 11 2020 Hits: 86 Rating: 0.00 Votes: 0) Rate It

• Jeol starts Micro Sessions - Live slots, remote demos or on-demand webinars, as a manufacturer of high-tech electron microscopes and analytical systems for research and industry, JEOL is increasing its focus on digital networking now. On July 10th, 2020, JEOL Germany is launching its new digital series “Micro Sessions” in English, in which current research topics and system demonstrations will be broadcasted live from the demo laboratory at the German location in Freising to the world wide web. A team of 6 JEOL application specialists will give tips for high-precision and efficient work on modern electron microscopes for the first time on July 10th with weekly following new slots. The first online series of topics in this year´s summer is divided into a general introductory part on the advantages of scanning electron microscopy, a second slot for residual dirt analysis and a slot three for technical cleanliness and gunshot residue. The slots, which are moderated in tandem, are offered live in German and English and show practical techniques and benefits of modern analytical methods. As part of the embedded Q&A expert group, the application specialists will answer the questions asked by the participants/viewers. Participation in the Micro Session series is free of charge for users. Pre-registration for the three individual slots in English is available via the accreditation URL at https://www.edudip.com/en/webinar/high-precision-and-efficient-work-on-modern-electron-microscopes-3-sessions/357906 By actively linking best practice examples with a respective live presentation on the modern JEOL electron microscopy systems, partially controlled by questions from the registered online audience from materials science, life science and industry, with the new format " Micro Sessions” JEOL provides digital insights into the world of microscopy and sets new impulses in an interactive openness, true to the slogan of the Japanese high-tech company “Solutions for Innovation”. Further formats with a high degree of user orientation are expected to follow online and offline. In the future, JEOL will also offer individual training courses tailored to the special questions of customers from natural sciences, medicine, materials science, semiconductor technology, automotive or aerospace remotely and on site at the in-house academy in Freising. About the company: JEOL is the world's largest provider of analytical systems for materials research, nanotechnology, medicine, biology and biotechnology. With over 3,000 employees worldwide, various systems for microscopy imaging of surfaces and internal structures of matter as well as systems for analyzing the chemical composition in the micro and nano range are developed and manufactured. Through years of experience, unique technologies, products and services, JEOL enables to offer its customers significant breakthroughs in product development and research. The German subsidiary of the Japanese high-tech company is based in Freising near Munich. From its German headquarters, JEOL takes care of sales and service of the JEOL systems in 16 countries in Europe and Africa (Added: Fri Jul 10 2020 Hits: 52 Rating: 0.00 Votes: 0) Rate It

• Jeol starts Micro Sessions - Live slots, remote demos or on-demand webinars, as a manufacturer of high-tech electron microscopes and analytical systems for research and industry, JEOL is increasing its focus on digital networking now. On July 10th, 2020, JEOL Germany is launching its new digital series “Micro Sessions” in English, in which current research topics and system demonstrations will be broadcasted live from the demo laboratory at the German location in Freising to the world wide web. A team of 6 JEOL application specialists will give tips for high-precision and efficient work on modern electron microscopes for the first time on July 10th with weekly following new slots. The first online series of topics in this year´s summer is divided into a general introductory part on the advantages of scanning electron microscopy, a second slot for residual dirt analysis and a slot three for technical cleanliness and gunshot residue. The slots, which are moderated in tandem, are offered live in German and English and show practical techniques and benefits of modern analytical methods. As part of the embedded Q&A expert group, the application specialists will answer the questions asked by the participants/viewers. Participation in the Micro Session series is free of charge for users. Pre-registration for the three individual slots in English is available via the accreditation URL at https://www.edudip.com/en/webinar/high-precision-and-efficient-work-on-modern-electron-microscopes-3-sessions/357906 By actively linking best practice examples with a respective live presentation on the modern JEOL electron microscopy systems, partially controlled by questions from the registered online audience from materials science, life science and industry, with the new format " Micro Sessions” JEOL provides digital insights into the world of microscopy and sets new impulses in an interactive openness, true to the slogan of the Japanese high-tech company “Solutions for Innovation”. Further formats with a high degree of user orientation are expected to follow online and offline. In the future, JEOL will also offer individual training courses tailored to the special questions of customers from natural sciences, medicine, materials science, semiconductor technology, automotive or aerospace remotely and on site at the in-house academy in Freising. About the company: JEOL is the world's largest provider of analytical systems for materials research, nanotechnology, medicine, biology and biotechnology. With over 3,000 employees worldwide, various systems for microscopy imaging of surfaces and internal structures of matter as well as systems for analyzing the chemical composition in the micro and nano range are developed and manufactured. Through years of experience, unique technologies, products and services, JEOL enables to offer its customers significant breakthroughs in product development and research. The German subsidiary of the Japanese high-tech company is based in Freising near Munich. From its German headquarters, JEOL takes care of sales and service of the JEOL systems in 16 countries in Europe and Africa (Added: Fri Jul 10 2020 Hits: 57 Rating: 0.00 Votes: 0) Rate It

• Jeol starts Micro Sessions - Live slots, remote demos or on-demand webinars, as a manufacturer of high-tech electron microscopes and analytical systems for research and industry, JEOL is increasing its focus on digital networking now. On July 10th, 2020, JEOL Germany is launching its new digital series “Micro Sessions” in English, in which current research topics and system demonstrations will be broadcasted live from the demo laboratory at the German location in Freising to the world wide web. A team of 6 JEOL application specialists will give tips for high-precision and efficient work on modern electron microscopes for the first time on July 10th with weekly following new slots. The first online series of topics in this year´s summer is divided into a general introductory part on the advantages of scanning electron microscopy, a second slot for residual dirt analysis and a slot three for technical cleanliness and gunshot residue. The slots, which are moderated in tandem, are offered live in German and English and show practical techniques and benefits of modern analytical methods. As part of the embedded Q&A expert group, the application specialists will answer the questions asked by the participants/viewers. Participation in the Micro Session series is free of charge for users. Pre-registration for the three individual slots in English is available via the accreditation URL at https://www.edudip.com/en/webinar/high-precision-and-efficient-work-on-modern-electron-microscopes-3-sessions/357906 By actively linking best practice examples with a respective live presentation on the modern JEOL electron microscopy systems, partially controlled by questions from the registered online audience from materials science, life science and industry, with the new format " Micro Sessions” JEOL provides digital insights into the world of microscopy and sets new impulses in an interactive openness, true to the slogan of the Japanese high-tech company “Solutions for Innovation”. Further formats with a high degree of user orientation are expected to follow online and offline. In the future, JEOL will also offer individual training courses tailored to the special questions of customers from natural sciences, medicine, materials science, semiconductor technology, automotive or aerospace remotely and on site at the in-house academy in Freising. About the company: JEOL is the world's largest provider of analytical systems for materials research, nanotechnology, medicine, biology and biotechnology. With over 3,000 employees worldwide, various systems for microscopy imaging of surfaces and internal structures of matter as well as systems for analyzing the chemical composition in the micro and nano range are developed and manufactured. Through years of experience, unique technologies, products and services, JEOL enables to offer its customers significant breakthroughs in product development and research. The German subsidiary of the Japanese high-tech company is based in Freising near Munich. From its German headquarters, JEOL takes care of sales and service of the JEOL systems in 16 countries in Europe and Africa (Added: Fri Jul 10 2020 Hits: 72 Rating: 0.00 Votes: 0) Rate It

• Jeol starts Micro Sessions - Live slots, remote demos or on-demand webinars, as a manufacturer of high-tech electron microscopes and analytical systems for research and industry, JEOL is increasing its focus on digital networking now. On July 10th, 2020, JEOL Germany is launching its new digital series “Micro Sessions” in English, in which current research topics and system demonstrations will be broadcasted live from the demo laboratory at the German location in Freising to the world wide web. A team of 6 JEOL application specialists will give tips for high-precision and efficient work on modern electron microscopes for the first time on July 10th with weekly following new slots. The first online series of topics in this year´s summer is divided into a general introductory part on the advantages of scanning electron microscopy, a second slot for residual dirt analysis and a slot three for technical cleanliness and gunshot residue. The slots, which are moderated in tandem, are offered live in German and English and show practical techniques and benefits of modern analytical methods. As part of the embedded Q&A expert group, the application specialists will answer the questions asked by the participants/viewers. Participation in the Micro Session series is free of charge for users. Pre-registration for the three individual slots in English is available via the accreditation URL at https://www.edudip.com/en/webinar/high-precision-and-efficient-work-on-modern-electron-microscopes-3-sessions/357906 By actively linking best practice examples with a respective live presentation on the modern JEOL electron microscopy systems, partially controlled by questions from the registered online audience from materials science, life science and industry, with the new format " Micro Sessions” JEOL provides digital insights into the world of microscopy and sets new impulses in an interactive openness, true to the slogan of the Japanese high-tech company “Solutions for Innovation”. Further formats with a high degree of user orientation are expected to follow online and offline. In the future, JEOL will also offer individual training courses tailored to the special questions of customers from natural sciences, medicine, materials science, semiconductor technology, automotive or aerospace remotely and on site at the in-house academy in Freising. About the company: JEOL is the world's largest provider of analytical systems for materials research, nanotechnology, medicine, biology and biotechnology. With over 3,000 employees worldwide, various systems for microscopy imaging of surfaces and internal structures of matter as well as systems for analyzing the chemical composition in the micro and nano range are developed and manufactured. Through years of experience, unique technologies, products and services, JEOL enables to offer its customers significant breakthroughs in product development and research. The German subsidiary of the Japanese high-tech company is based in Freising near Munich. From its German headquarters, JEOL takes care of sales and service of the JEOL systems in 16 countries in Europe and Africa (Added: Fri Jul 10 2020 Hits: 56 Rating: 0.00 Votes: 0) Rate It

• Ceftriaxone Sodium API Market – Insights on Emerging Trends 2024 - This report provides in-depth study on the current state of the Global Ceftriaxone Sodium API Market 2020-2024. Key players in the Global Ceftriaxone Sodium API Market have been identified through the secondary research and their market share has been determined through primary and secondary research. Global Ceftriaxone Sodium API Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size. Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/267902 . Ceftriaxone, sold under the brand name Rocephin, is an antibiotic used for the treatment of a number of bacterial infections. These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. It is also sometimes used before surgery and following a bite wound to try to prevent infection. Ceftriaxone can be given by injection into a vein or into a muscle. The Global Ceftriaxone Sodium API Market is segmented on the basis of Product Type, Application, End Use Industry and Region. On the Basis of Product Type segment, the Ceftriaxone Sodium API Market is sub segmented into>99.5 and>99.8. Based on End Use Industry segment, the Ceftriaxone Sodium API Market is sub segmented into Powder Injection and Injection. Some of the Ceftriaxone Sodium API Market manufacturers involved in the market are United Laboratories, Union Chempharma, NCPC, Sinopharm Sandwich, Fujian Fukang Pharmaceutical, Youcare Pharmaceutical, Shanghai Pharmaceutical, Livzon Pharmaceutical, Qilu Antibiotics Pharmaceutical, Lupin Pharmaceuticals, Hospira in World, effective mergers are some of the strategies adopted by the Ceftriaxone Sodium API Market manufacturers. New product launches and continuous technological innovations are the Ceftriaxone Sodium API Market strategies adopted by the major players. Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Ceftriaxone Sodium API Market Report 2020” @ https://www.businessindustryreports.com/buy-now/267902/single . The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. There are several manufacturers of Ceftriaxone Sodium API in Europe and North America. In North America, the demand for Ceftriaxone Sodium API is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/267902 . Top Industry News: Abiraterone Acetate Tablets exported to US on 20 Jan, 2020 -- Qilu Pharmaceutical announced Abiraterone Acetate Tablets was exported to the US on January 20, 2020. Up to now, Qilu has exported fourteen products to US and among them, ten products are the injectables. The total volume of finished formulations exported to US is over 100 million units in 2019, increasing 160% compared with 2018. Several products ranked top 3 in US market. Table of Contents: 1 Ceftriaxone Sodium API Product Definition 2 Global Ceftriaxone Sodium API Market Manufacturer Share and Market Overview 2.1 Global Manufacturer Ceftriaxone Sodium API Shipments 2.2 Global Manufacturer Ceftriaxone Sodium API Business Revenue 2.3 Global Ceftriaxone Sodium API Market Overview 2.4 COVID-19 Impact on Ceftriaxone Sodium API Industry 3 Manufacturer Ceftriaxone Sodium API Business Introduction 3.1 United Laboratories Ceftriaxone Sodium API Business Introduction 3.1.1 United Laboratories Ceftriaxone Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.1.2 United Laboratories Ceftriaxone Sodium API Business Distribution by Region 3.1.3 United Laboratories Interview Record 3.1.4 United Laboratories Ceftriaxone Sodium API Business Profile 3.1.5 United Laboratories Ceftriaxone Sodium API Product Specification 3.2 Union Chempharma Ceftriaxone Sodium API Business Introduction 3.2.1 Union Chempharma Ceftriaxone Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.2.2 Union Chempharma Ceftriaxone Sodium API Business Distribution by Region 3.2.3 Interview Record 3.2.4 Union Chempharma Ceftriaxone Sodium API Business Overview 3.2.5 Union Chempharma Ceftriaxone Sodium API Product Specification 3.3 NCPC Ceftriaxone Sodium API Business Introduction 3.3.1 NCPC Ceftriaxone Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.3.2 NCPC Ceftriaxone Sodium API Business Distribution by Region 3.3.3 Interview Record 3.3.4 NCPC Ceftriaxone Sodium API Business Overview 3.3.5 NCPC Ceftriaxone Sodium API Product Specification 3.4 Sinopharm Sandwich Ceftriaxone Sodium API Business Introduction 3.5 Fujian Fukang Pharmaceutical Ceftriaxone Sodium API Business Introduction 3.6 Youcare Pharmaceutical Ceftriaxone Sodium API Business Introduction ………………. Request free sample to get a complete Table of Content About us BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Media Contact Business Industry Reports Pune – India sales@businessindustryreports.com +19376349940 (Added: Tue Jul 07 2020 Hits: 64 Rating: 0.00 Votes: 0) Rate It

• Cefminox Sodium API Market – Insights on Emerging Trends 2024 - Global Cefminox Sodium API Market 2020-2024 examines the market in detail along with focusing on significant market dynamics for the key players in the market. This research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global Cefminox Sodium API Market: Cefminox Sodium is the sodium salt form of cefminox, a semi-synthetic, second-generation, beta-lactamase-stable cephalosporin with antibacterial activity. Cefminox sodium is a second generation β-lactam cephalosporin antibiotic that also a sodium salt. Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Cefminox Sodium API market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects. Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/267899 . Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Cefminox Sodium API costs and an increase in the number of sodium salt form of cefminox, a semi-synthetic, second-generation, beta-lactamase-stable cephalosporin with antibacterial activity. Product Type Segmentation: The Cefminox Sodium API market have different product type such as>99.5 and>99.8. Cefminox Sodium API market product type gives sodium salt form of cefminox, a semi-synthetic, second-generation, beta-lactamase-stable cephalosporin with antibacterial activity. Industry Segmentation: Increasing instances across various sectors such as Powder Injection and Injection are raising the need of chemical institutes, thereby raising the demand for Cefminox Sodium API market. This help in the profitable growth of the Global Cefminox Sodium API market in upcoming year. Segmentation by Regions: The Cefminox Sodium API market in North America has created sodium salt form of cefminox, a semi-synthetic, second-generation, beta-lactamase-stable cephalosporin with antibacterial activity to help chemical industries in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Cefminox Sodium API Market during the forecast year. Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Cefminox Sodium API Market Report 2020” @ https://www.businessindustryreports.com/buy-now/267899/single . Top Leading Key Manufacturers are: United Laboratories, Union Chempharma, NCPC, Sinopharm Sandwich, Fujian Fukang Pharmaceutical, Youcare Pharmaceutical, Shanghai Pharmaceutical. New product launches and continuous technological innovations are the key strategies adopted by the major players. Top Industry News: NCPC APPROVES FINAL MASTER PLAN FOR THE SMITHSONIAN’S SUITLAND COLLECTIONS CENTER ON 05 JUNE, 2020 -- the National Capital Planning Commission (NCPC) approved the final master plan for the Smithsonian Institution’s Suitland Collections Center located in Suitland, Maryland. Since the 1950’s the center has been one of the Smithsonian’s primary locations to store collections not on display in its museums. However, the growth of its collections storage has not kept pace with collection needs, leading to outdated and overcrowded facilities. The 110-acre site currently includes 1.3 million square feet of space located in multiple facilities, which the Smithsonian proposes to increase to 2.4 million square feet. This includes a new collection building, relocation of select buildings, and the demolition of outdated facilities. The Smithsonian will implement the plan, which is connected to several other museum projects, in phases over the next few decades. Commissioners supported the proposed layout of the new storage buildings that would be built around a common open space connecting to the campus’ administrative buildings, and appreciated the plan enhancements and changes that were made in response to previous NCPC comments. These include an update to achieve a 1:3 parking ratio (one parking spot per three employees), reduction of the number of parking spaces onsite, and an update to the campus’s Transportation Management Plan that will take place in FY 2021. Smithsonian staff will also meet with the National Park Service, Maryland State Highway Administration, and the General Services Administration to discuss ways to improve pedestrian and bicycle connections to the nearby Suitland Metro station that are currently unsafe. While Commissioners agreed that a proposed new perimeter security fence is justified to protect the center’s important collections, they deferred looking at specifics such as location, height, clearance zones, and lighting until the Smithsonian submits individual projects at the center for review, which is anticipated to begin around 2030. The Commission also required the Smithsonian to submit an updated security analysis with these future submissions. Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/267899 . Major Points in Table of Contents: 1 Cefminox Sodium API Product Definition 2 Global Cefminox Sodium API Market Manufacturer Share and Market Overview 2.1 Global Manufacturer Cefminox Sodium API Shipments 2.2 Global Manufacturer Cefminox Sodium API Business Revenue 2.3 Global Cefminox Sodium API Market Overview 2.4 COVID-19 Impact on Cefminox Sodium API Industry 3 Manufacturer Cefminox Sodium API Business Introduction 3.1 United Laboratories Cefminox Sodium API Business Introduction 3.1.1 United Laboratories Cefminox Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.1.2 United Laboratories Cefminox Sodium API Business Distribution by Region 3.1.3 United Laboratories Interview Record 3.1.4 United Laboratories Cefminox Sodium API Business Profile 3.1.5 United Laboratories Cefminox Sodium API Product Specification 3.2 Union Chempharma Cefminox Sodium API Business Introduction 3.2.1 Union Chempharma Cefminox Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.2.2 Union Chempharma Cefminox Sodium API Business Distribution by Region 3.2.3 Interview Record 3.2.4 Union Chempharma Cefminox Sodium API Business Overview 3.2.5 Union Chempharma Cefminox Sodium API Product Specification 3.3 NCPC Cefminox Sodium API Business Introduction 3.3.1 NCPC Cefminox Sodium API Shipments, Price, Revenue and Gross profit 2014-2019 3.3.2 NCPC Cefminox Sodium API Business Distribution by Region 3.3.3 Interview Record 3.3.4 NCPC Cefminox Sodium API Business Overview 3.3.5 NCPC Cefminox Sodium API Product Specification 3.4 Sinopharm Sandwich Cefminox Sodium API Business Introduction 3.5 Fujian Fukang Pharmaceutical Cefminox Sodium API Business Introduction 3.6 Youcare Pharmaceutical Cefminox Sodium API Business Introduction ………………. Request free sample to get a complete Table of Content About us BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Media Contact Business Industry Reports Pune – India sales@businessindustryreports.com +19376349940 (Added: Tue Jul 07 2020 Hits: 72 Rating: 0.00 Votes: 0) Rate It

• Delivering the Added Dimension in Scale-up - Webinar by Jubilant Biosys - Webinar Date: 7th July 2020 At the end of your discovery process and having selected your lead candidate, you now need pivotal TOX batches and GMP phase 1 material for IND submission. Medicinal chemistry is done at a low gram scale and the focus is finding the right molecular architecture, whereas the scale-up phase requires kilo range amounts often a 100X factor up from MedChem. Time is of the essence and as regulatory requirements are still forgiving in this early phase the temptation is to try and brute-force the ‘MedChem’ route. This can work with moderately complex routes but in recent years the majority of the candidates are the result of lengthy and complex synthetic schemes. The result can be a significant time loss combined with excessive cost and impurity generation leading to a frustrating experience as the chemistry does not behave the way we want it to. We will be discussing the transformation needed in decision-making, assessment, and bringing in scale-up expertise earlier than typically done through PR&D scientists. In addition, we offer a platform for all attendants to share their best practices and experience so IND submission can be accelerated with better chemistry and technology decisions including the right focus on process impurities in human trials. Common assumptions seen in practices: • Why lose time on a new route? “We need it fast, let us make it this way” • “My route is better” • Medicinal chemists have been seen to be satisfied with their route in 70 % of the cases (what is the source of this statement?) Foreseeable Engineering & Technology aspect: • Need for Column chromatography • Use of SFC – rather an avoidance of it • Isolation issues and other purification aspects Foreseeable regulatory aspects: • The solvents & catalysts being used • Impurities • Use of cleanroom Applicability of technology: • Use of flow/photochemistry Analytical aspects: • Level of details in the qualification of API – what assay level is best? • Techniques needed for the qualification of material • Setting up the limits for impurities, metals, OVI, moisture • Solid-state characterization – when to do it? Final recommendation and discussion Webinar Speakers: 1. Marcel Velterop President – Drug Discovery Services & CDMO – Jubilant Biosys Limited Marcel J. Velterop, as President Drug Discovery Services & CDMO will lead Jubilant Drug Discovery Services and Contract Development & Manufacturing Organisation (CDMO) to provide an integrated solution to our life science customers from drug development to scale-up and then commercial manufacturing designed for maximum speed and compliance. Marcel brings over 25 years of business, pharmaceutical & CDMO experience and leadership to JDDS. 2. Dr. Vikas Shirsath Senior Vice President – Global Operations – Jubilant Biosys Limited Dr. Vikas Shirsath is a creative, result-oriented medicinal chemist with broad experience in drug discovery operations including medicinal, synthetic chemistry, biology, and IP management with major contributions in the area of CNS therapeutics. During his 15 years of industrial experience with drug discovery services in India, he has led the science, operations, IP strategies and has mainly contributed to the growth of two start-up companies which grew to the critical mass of 250 teams. 3. Purushotham Vandanapu Director – Scale-up Chemistry Operations – Jubilant Biosys Limited Mr. Vandanapu has more than 26 years of experience in Process Development of New Chemical entity and Active Pharmaceutical Ingredients. He started his career from Neuland Laboratories Ltd, Hyderabad where he worked as a Junior Chemist. Post this he was associated with Pharmed Chemicals Ltd, Bangalore, Dr.Reddy’s Laboratories Ltd, CPS, Hyderabad, Glenmark Research Centre, Navi Mumbai, Sai Advantium Pharmaceuticals Ltd, Hyderabad and AstraZeneca India Pvt Ltd, GCD, Bangalore. About Jubilant Biosys Limited: Jubilant Biosys, a subsidiary of Jubilant Life Sciences Limited, is a Contract Research Organization with its R&D centers in India and business offices in Asia and North America. Jubilant Biosys specializes in comprehensive drug discovery services for the global pharmaceutical industry. In order to be the preferred collaborator in the drug discovery domain, Jubilant Biosys is committed to comply with and continually improve its quality systems. With having strong clinical development, Jubilant Biosys has risen as a fully integrated contract research organization in India and headquartered at Bengaluru with end-to-end solutions. Jubilant Biosys Limited Bengaluru Research Site: #96, Industrial Suburb 2nd Stage, Yeshwantpur Bangalore - 560 022 Karnataka India. Tel: +91-8066628400 For more info: www.jubilantbiosys.com/webinar/ (Added: Wed Jul 01 2020 Hits: 74 Rating: 0.00 Votes: 0) Rate It

• Global Industrial Microbiology Market Status and Future Forecast 2015-2025 - The report forecast global Industrial Microbiology market to grow to reach xx Million USD in 2020 with a CAGR of xx% during the period 2020-2025. The report offers detailed coverage of Industrial Microbiology industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Industrial Microbiology by geography. The report splits the market size, by volume and value, on the basis of application type and geography. First, this report covers the present status and the future prospects of the global Industrial Microbiology market for 2015-2025. And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]. At the same time, we classify Industrial Microbiology according to the type, application by geography. More importantly, the report includes major countries market based on the type and application. Finally, the report provides detailed profile and data information analysis of leading Industrial Microbiology company. Key Content of Chapters as follows (Including and can be customized) : Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Global Market by company, Type, Application & Geography Part 3-4: Asia-Pacific Market by company, Type, Application & Geography Part 5-6: Europe Market by company, Type, Application & Geography Part 7-8: North America Market by company, Type, Application & Geography Part 9-10: South America Market by company, Type, Application & Geography Part 11-12: Middle East & Africa Market by company, Type, Application & Geography Part 13: Company information, Sales, Cost, Margin etc. Part 14: Conclusion (Added: Thu Jun 25 2020 Hits: 265 Rating: 0.00 Votes: 0) Rate It

• Material Science Congress - Global Episteme invites all the participants to attend Material Science Congress which to be held in Rome, Italy during March 31-April 01, 2021 In the light of theme - Material Science of today is the innovation of tomorrow, Material Science Congress aims to provide a forum for international researchers and academicians from various areas of chemistry, pharmacy, materials science and chemical engineering by providing one kind of platform for critical analysis of new designing, and to share latest cutting-edge research findings, most recent movements and latest upgrades inside the field of Nanotech and Material Science with explicit keynote lectures, plenary sessions, Poster competition, Young Researchers’ Forum (YRF), Workshops, Symposiums and Exhibitions from elite researchers, distinguished scientists and business delegates. It allows delegates to have issues addressed on Nanotechnology and Materials Science by recognized global experts who are up to date with the latest developments in the field of materials science and manufacturing technology to a common forum. (Added: Tue Jun 09 2020 Hits: 61 Rating: 0.00 Votes: 0) Rate It

• Pivotal Scientific advises EastCoast Bio on its sale to Medix Biochemica - A successful transaction benefitting both parties. Pivotal Scientific is delighted to announce its assistance in the sale of US based biotech firm EastCoast Bio to the Finnish leading supplier of IVD products, Medix Biochemica. The acquisition will broaden Medix Biochemica’s product portfolio for the IVD manufacturing industry worldwide and expand their US presence, whilst EastCoast Bio will benefit from Medix Biochemica’s strong commercial presence in Europe and China. Pivotal Scientific Limited supported EastCoast Bio throughout the entire process including strategy for forward planning, all M&A documentation and agency management. Our expert knowledge of the global biotech landscape helped us prepare them for a seamless integration offering competitive advantages for both companies and ensuring sustainable value. “PSL really helped us get ready for sale and managed the process on an end to end basis which allowed my team and I to keep doing what we do best which is serving customers” Clark Macdermith, EastCoast Bio “We have been working with EastCoast Bio for nearly two years, originally supporting their planning for continued growth and then in 2019 we started to promote the company for sale. EastCoast Bio has been very successful and delivered sustained growth so the opportunity to come together with Medix Biochemica is beneficial for both companies and customers, especially with such an impressive and comprehensive product range now available” Tim Bernard, CEO, Pivotal Scientific Limited (Added: Mon Jun 08 2020 Hits: 82 Rating: 0.00 Votes: 0) Rate It

• 2nd Edition of Neuroscience & Mental Disorders - After the completion of our 1st Edition of Neuroscience & Mental Disorders at Rome, Italy during July 01 - 02, 2019, We are pleased to announce our 2nd Edition of Neuroscience & Mental Disorders to be held at London, UK on March 15 – 16, 2021. Neuroscience 2021 showcases the best medical practices in the world, and provides a one-of-a-kind forum to explore the complete spectrum of neurology from basic science to translation and application. We aim to narrow in on your scientific niche, and connect with the experts in your field (Added: Wed Jun 03 2020 Hits: 65 Rating: 0.00 Votes: 0) Rate It

Pages: [<<] ... 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... [>>]